Blue Trust Inc’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Blue Trust Inc’s Portfolio CINC Stock Details CINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14	Closed	–	–	2557
2022 Q3	$0	Buy	+14	New	+$396	﹤0.01%	2407

Other funds holding CINC

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Blue Trust Inc's CINC Position: Q4 2022 in Review

Blue Trust Inc sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q4 2022, closing a stake of 14 shares.

Blue Trust Inc first reported a position in CINC in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 102 funds tracked by Wall St. Rank hold CINC as of Q4 2022.

Blue Trust Inc reported no remaining CinCor Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Blue Trust Inc sold 14 CinCor Pharma, Inc. Common Stock shares in Q4 2022.
Blue Trust Inc first reported a position in CinCor Pharma, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
Blue Trust Inc's CinCor Pharma, Inc. Common Stock position peaked at $0 in Q3 2022.
102 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q4 2022.

Based on Blue Trust Inc's 13F filing for Q4 2022, filed 17 Jan 2023.